Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - oestradiol - unknown - oestradiol steroid-estrogen active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

syntex s.a. - oestradiol cypionate - unknown - oestradiol cypionate steroid-estrogen active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

avet health limited - oestradiol benzoate - parenteral liquid/solution/suspension - oestradiol benzoate steroid-estrogen active 1.0 mg/ml - endocrine system

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme australia pty ltd - oestradiol hemihydrate; nomegestrol acetate -

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - drospirenone; oestradiol hemihydrate; oestradiol -

Israel - English - Ministry of Health

bayer israel ltd - drospirenone; estradiol as hemihydrate - film coated tablets - drospirenone 2 mg; estradiol as hemihydrate 1 mg - estradiol - estradiol - angeliq is indicated for hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women more than 1 year post menopause. prevention of postmenopausal osteoporosis in women with an increased risk of future osteoporosis fractures.

United States - English - NLM (National Library of Medicine)

ge healthcare inc. - fluoroestradiol f-18 (unii: t32277kb09) (fluoroestradiol f-18 - unii:t32277kb09) - cerianna is indicated for use with positron emission tomography (pet) imaging for the detection of estrogen receptor (er)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. limitations of use tissue biopsy should be used to confirm recurrence of breast cancer and to verify er status by pathology. cerianna is not useful for imaging other receptors, such as human epidermal growth factor receptor 2 (her2) and the progesterone receptor (pr). none. risk summary all radiopharmaceuticals, including cerianna, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of radiation dose. advise a pregnant woman of the potential risks of fetal exposure to radiation from administration of cerianna. there are no available data on cerianna use in pregnant women. no animal reproduction studies using fluoroestradiol f 18 have been conducted to evaluate its effect on female reproduction and embryo-fetal development. the estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. all pregnancies have a background risk of birth defects, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. risk summary there are no data on the presence of fluoroestradiol f 18 in human milk, or its effects on the breastfed infant or milk production. lactation studies have not been conducted in animals. advise a lactating woman to avoid breastfeeding for 4 hours after cerianna administration in order to minimize radiation exposure to a breastfed infant. the safety and effectiveness of cerianna in pediatric patients have not been established. clinical studies of fluoroestradiol f 18 injection did not reveal any difference in pharmacokinetics or biodistribution in patients aged 65 and over.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - oestradiol benzoate; progesterone; detectable marker - parenteral implant, device - oestradiol benzoate steroid-estrogen active 10.0 mg/im; progesterone steroid-progestin active 100.0 mg/im; detectable marker miscellaneous other 0.0 p - nutrition & metabolism - calf | beef calf | bovine | calf - poddy | calf - preweaning | calf - sucker | dairy calf | neonatal calf - promote animal growth | feed conversion | finishing | growth promotion | growth rate | liveweight gain

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - canagliflozin hemihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - canagliflozin hemihydrate -